Document is current
Any future updates will be listed below
-
Authors
Ohira, Masahiro
Hotta, Ryuichi
Tanaka, Yuka
Matsuura, Toshiharu
Tekin, Akin
Selvaggi, Gennaro
Vianna, Rodrigo
Ricordi, Camillo
Ruiz, Phillip
Nishida, Seigo
Tzakis, Andreas G.
Ohdan, Hideki http://orcid.org/0000-0002-9066-1288
-
Funding
Funding for this research was provided by:
the Florida Department of Health and the Bankhead-Coley Cancer Research Program (1BG-08)
Japan Agency for Medical Research and Development (JP21fk0210051)
Japan Society for the Promotion of Science (JP20K09104)
- License Information
-
More Information
Article History
Received: 17 May 2021
Accepted: 29 June 2021
First Online: 19 July 2021
Declarations
:
: The authors of this manuscript have no conflict of interest to disclose as described by the Cancer Immunology, Immunotherapy.
: This phase I clinical trial was approved by the Institutional Review Board of the University of Miami Miller School of Medicine (IRB#20100344) and the Food and Drug Administration, and was registered with ClinicalTrials.gov (NCT01147380). The trial was designed and conducted according to the Declaration of Helsinki.
: All patients provided written informed consent before enrolling in the study.
